Phase II study of roquinimex in myelodysplastic syndrome

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 2, 1997, Pages 189-192

  Rosenfeld, Craig S ^a   Zeigler, Zella R ^b   Shadduck, Richard K ^b   Nilsson, Bo ^c  

^a TEXAS ONCOLOGY   (United States)

^b W Pennsylvania Cancer Institute   (United States)

^c PFIZER INC   (United States)

Author keywords

Myelodysplastic syndromes; Phase II trial; Roquinimex

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; ERYTHROPOIETIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; ROQUINIMEX;

ARTHRALGIA; ARTICLE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; FEVER; HEADACHE; HUMAN; IMMUNE RESPONSE; MULTICENTER STUDY; MYALGIA; MYELODYSPLASTIC SYNDROME; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRELEUKEMIA;

ADJUVANTS, IMMUNOLOGIC; AGED; FEMALE; HEMATOPOIESIS; HUMANS; HYDROXYQUINOLINES; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES;

EID: 0030978289     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199704000-00018     Document Type: Article

References (25)

1. Paquette RL, Koeffler P. Differentiation therapy. Hematol Oncol Clin North Am 1992;6:687.
2. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol 1991;77: 502-8.
3. Zeigler ZR, Jones D, Rosenfeld CS, et al. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome. Stem Cells 1993;11:49-55.
4. Ganser A, Hoelzer D. Treatment of myelodysplastic syndromes with hematopoietic growth factors. Hematol Oncol Clin North Am 1992;6:633.
5. Gordon MS, Nemunaitis J, Hoffman R, et al. Phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995;85: 3066-76.
6. Löffler H. Schmitz N, Gassmann W. Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:619.
7. Cheson BD, Jasperse DM, Simon R, Friedman MA. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986;4:1857-64.
8. Hamblin T. Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am 1992;6:571.
9. Ogata K, Yokose N, Ito T, An E, Dan K, Nomura T. Effects of interleukin 2 on myelodysplastic syndromes. Leuk Res 1993;17:137-142.
10. Foa R. Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol 1993;11:1817-25.
11. Bagby GC, Gabourel JD, Linman JW. Glucocorticoid therapy in the preleukemic syndrome (hemopoietic dysplasia). Ann Intern Med 1980;92:55-8.
12. List AF, Glinsmann-Gibson B, Spier C, Taetle R. In vitro and in vivo response to cyclosporin-A in myelodysplastic syndromes (MDS): identification of a hypocellular subset responsive to immune suppression. Blood 1992;89(suppl 1):103.
13. Sulecki M, Shadduck RK, Zeigler Z. Anti-thymocyte globulin for hypoplastic myelodysplastic syndrome. Blood 1988; 72(suppl 1):827.
14. Galvani DW, Nethersell ABW, Cawley JC. α-Interferon in myelodysplasia: clinical observations and effects on NK cells. Leuk Res 1988;12:257-62.
15. Toze CL, Barnett MJ, Klingemann HG. Response of therapy-related myelodysplasia to low-dose interleukin-2. Leukemia 1993;7:463-5.
16. Rowe JM, Nilsson BI, Simonsson B. Treatment of minimal residual disease in myeloid leukemia: the immunotherapeutic options with emphasis on linomide. Leuk Res 1993;11:321-9.
17. Bengtsson M, Simonsson B, Carlsson K, et al. Stimulation of NK cell, T cell, and monocyte functions by the novel immunomodulator linomide after autologous bone marrow transplantation. Transplantation 1992;53:882-8.
18. Rosenfeld CS. Potential of phenylalanine methylester as a bone marrow purging agent. Blood 1992;80:2401-5.
19. Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal 1990;4:102.
20. van Kamp H, Fibbe WE, Jansen RPM, et al. Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 1992;80:1774-80.
21. van den Brink MRM, Voogt PJ, Marijt WAF, van Luxemburg-Heys SAP, van Rood JJ, Brand A. Lymphokine-activated killer cells selectively kill tumor cells in bone marrow without compromising bone marrow stem cell function in vitro. Blood 1989;74:354-60.
22. Murphy WJ, Reynolds CW, Tiberghien P, Longo DL. Natural killer cells and bone marrow transplantation. J Natl Cancer Inst 1993;85:1475-82.
23. Robertson MJ, Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990;76:2421-38.
24. Nilsson BI, Simonsson B, Bengtsson M, Totterman TH, Johansson C, Row JM. Immunotherapy of AML after ABMT: scientific rationale and early experiences with linomide. Autologous Bone Marrow Transplantation Proceedings of the Sixth International Symposium. Arlington: Cancer Treatment Research Education Fund. 1993:38-44.
25. Herold M, Schmalzl F, Zwierzina H. Increased serum interleukin 6 levels in patients with myelodysplastic syndromes. Leuk Res 1992;16:585-8.